OR WAIT null SECS
August 06, 2020
The expanded facility will feature two new 40-L and 300-L manufacturing vessels, a capsule filling line, and six drying tunnels that will add more than 10 million doses per annum to the site.
The new facility will give the company’s Australian customers access to tablet formulation and coating services in order to shorten supply chains and increase the region’s pharmaceutical sector capacity.
The expansion will involve using the facilities’ existing central utilities and labs to supplement its small-scale and large-scale assets.
August 03, 2020
The investment will allow for the expansion of analytical R&D efforts and will support the company’s reference materials business.
August 01, 2020
CMOs and CDMOs expanded their services and facilities in 2020.
July 08, 2020
The acquisition will give the CDMO additional clinical filling options in Europe, which is expected to come online in 2021.
July 07, 2020
The new site will offer initial design and development, low-volume manufacturing, and scalable high-quality production of wearable drug delivery devices.
July 02, 2020
The new facility in Grand Rapids, MI, is part of the CDMO’s aggressive expansion plan.
Manufacturers must address scale-out challenges of autologous cell therapy for commercial manufacturing.
June 30, 2020
The site can now support customized product and bioprocess development and custom cell and gene therapy reagent manufacturing.